Transitioning from Bupropion SR and Escitalopram to Atomoxetine
Taper bupropion SR 100 mg daily over 1-2 weeks while maintaining escitalopram 5 mg, then discontinue escitalopram and initiate atomoxetine at 40 mg daily, titrating up after 3-7 days based on tolerability, with close monitoring for suicidality and cardiovascular effects.
Discontinuing Bupropion SR
Taper the bupropion gradually rather than stopping abruptly to minimize discontinuation symptoms 1. Although the FDA labeling specifically addresses tapering from 300 mg daily doses, the principle applies to lower doses:
- Continue bupropion SR 100 mg daily for 1 week
- Reduce to 50 mg daily (half tablet) for 1 week if available, or discontinue after the first week if 50 mg formulation is unavailable 1
- The gradual taper minimizes seizure risk changes and withdrawal symptoms 1
Managing Escitalopram During Transition
Continue escitalopram 5 mg daily throughout the bupropion taper and for at least 1-2 weeks after bupropion discontinuation to maintain mood stability during the transition period. The low dose (5 mg) provides minimal SSRI coverage but helps bridge the gap.
Critical Drug Interaction Consideration
Be aware that escitalopram can significantly elevate atomoxetine levels through CYP2D6 inhibition 2. Research demonstrates that CYP2D6 inhibitors (which include SSRIs like escitalopram) can increase atomoxetine exposure substantially 3. One study showed bupropion increased atomoxetine exposure 5.1-fold when co-administered 3. While escitalopram's CYP2D6 inhibition is less potent than bupropion's, this interaction necessitates:
- Starting atomoxetine at a lower dose (40 mg daily rather than weight-based dosing)
- Slower titration schedule
- Enhanced monitoring for atomoxetine side effects (nausea, decreased appetite, somnolence) 2
Initiating Atomoxetine
Begin atomoxetine only after bupropion has been fully discontinued to avoid the significant drug-drug interaction that increases atomoxetine levels 5-fold 3. The transition sequence should be:
Week 1-2: Bupropion Taper
- Taper bupropion as described above while maintaining escitalopram 5 mg daily 1
Week 3: Washout and Escitalopram Discontinuation
- Allow 3-7 days after final bupropion dose before starting atomoxetine
- Discontinue escitalopram (5 mg is low enough that abrupt discontinuation is generally tolerated, though a brief taper to 2.5 mg for 3-5 days is reasonable if available)
Week 3-4: Atomoxetine Initiation
Start atomoxetine at 40 mg once daily in the morning 2. This conservative starting dose accounts for:
- Potential residual CYP2D6 inhibition from recently discontinued escitalopram
- Individual variation in CYP2D6 metabolism (7% of patients are poor metabolizers) 2
- Minimization of initial side effects (nausea, decreased appetite, somnolence) 2
Week 4 and Beyond: Titration
- After 3-7 days at 40 mg, increase to 60-80 mg daily if tolerated 2
- Target dose is typically 80-100 mg daily (or 1.2-1.4 mg/kg/day, whichever is lower) 2
- Divide doses if gastrointestinal side effects are problematic during titration 4, 5
- Allow 6-8 weeks minimum to assess full therapeutic response 4
Critical Monitoring Requirements
Suicidality Monitoring
Monitor closely for suicidal ideation, especially in the first few months and during dose changes 2. Atomoxetine carries a black box warning for increased suicidal thinking in children and adolescents, though this was not observed in adult trials 2. Given the patient is transitioning off antidepressants, this monitoring is essential regardless of age.
Cardiovascular Monitoring
Check blood pressure and heart rate at baseline and regularly during titration 2, 5. Research shows atomoxetine causes:
- Mean increases in heart rate of approximately 9 bpm 5
- Small but significant increases in both systolic and diastolic blood pressure (approximately 2-3 mmHg) 5
- These effects are generally mild but require monitoring, especially in patients with preexisting cardiovascular conditions 2
Psychiatric Symptom Monitoring
Watch for emergence or worsening of anxiety, agitation, or mood symptoms during the transition 2. The patient is losing both noradrenergic/dopaminergic coverage (bupropion) and serotonergic coverage (escitalopram), which may temporarily destabilize mood or anxiety symptoms before atomoxetine reaches therapeutic levels.
Common Pitfalls to Avoid
Do not start atomoxetine while the patient is still taking bupropion - the 5-fold increase in atomoxetine exposure creates significant risk for dose-related adverse effects including cardiovascular effects and potential hepatotoxicity 3.
Do not use rapid cross-titration - unlike switching between stimulants where cross-titration is feasible 4, 5, the pharmacokinetic interaction between bupropion and atomoxetine makes this approach dangerous 3.
Do not assume immediate therapeutic effect - atomoxetine requires 6-8 weeks for full assessment of efficacy, unlike the rapid onset seen with stimulants 4. Patients may experience a therapeutic gap during transition.
Do not overlook the indication change - if this patient was taking bupropion/escitalopram for depression rather than ADHD, atomoxetine is not FDA-approved for depression and showed no benefit over placebo when added to SSRIs for treatment-resistant depression 6. Ensure ADHD is the primary target diagnosis.